Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
RUT
Market Cap
1.02B
Enterprise Value
737.76M
Income
-138.54M
Sales
0.00M
Book/sh
7.42
Cash/sh
5.43
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
54
IPO
May 01, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
2.58
P/C
3.52
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
17.48
Current Ratio
17.48
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-2.59
EPS next Y
-2.45
EPS next Q
-0.56
EPS this Y
86.89%
EPS next Y
40.61%
EPS next 5Y
57.09%
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-17.10%
Sales Q/Q
-
Insider Own
74.22%
Insider Trans
0.05%
Inst Own
33.75%
Inst Trans
45.13%
ROA
-
ROE
-
ROIC
-34.59%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-6.97%
SMA50
-5.61%
SMA200
-5.23%
Trades
Shs Outstand
53.53M
Shs Float
13.80M
52W High
28.38 -32.64%
52W Low
14.85 28.75%
Volatility
6.73% 7.41%
ATR (14)
1.47
RSI (14)
43.19
Beta
-
Rel Volume
0.00
Avg Volume
241.30K
Volume
0
Perf Week
-12.79%
Perf Month
7.24%
Perf Quarter
-20.23%
Perf Half Y
21.47%
Perf YTD
-8.95%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
19.12
Price
19.12
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$37.12
Implied Upside
+94.1%
Analysts7incl. previous ratings
Rating Distribution7 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 14, 2026Initiated
CCanaccord Genuity
Buy$28+46.4%
Sep 25, 2026Initiated
RJF logoRRaymond James
Strong Buy$46+140.6%
Jul 15, 2026Initiated
HH.C. Wainwright
Buy$50+161.5%
May 26, 2026Initiated
SF logoSStifel
Buy$30+56.9%
May 26, 2026Initiated
LLeerink Partners
Outperform$35+83.1%
May 26, 2026Initiated
JPM logoJJP Morgan
Overweight$42+119.7%
May 26, 2026Initiated
C logoCCitigroup
Buy$35+83.1%
Nov-02-26 06:00AM
Oct-28-26 07:00AM
Oct-09-26 01:00PM
07:00AM
Oct-07-26 01:00PM
07:00AM Loading…
07:00AM
Sep-22-26 03:00PM
Sep-14-26 07:00AM
Sep-09-26 01:13PM
07:00AM
Aug-31-26 07:00AM
Aug-26-26 09:41AM
Aug-03-26 07:00AM
Jun-09-26 02:00AM
Jun-08-26 07:00AM
07:00AM Loading…
Jun-01-26 07:00AM
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Torres DeniceDirectorNov 03 '26Buy19.865,00099,3255,000Nov 04 07:30 AM
HOMBACH ROBERT J.DirectorJun 22 '26Buy18.1413,000235,76813,000Jun 24 06:05 AM
ARCH Venture Partners XII, LLC10% OwnerMay 04 '26Buy18.001,100,00019,800,0006,294,951May 04 06:02 PM
Seaport Therapeutics, Inc. is a clinical-stage therapeutics company, which engages in the provision of inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company was founded on April 1, 2024 and is headquartered in Boston, MA.
Founder & Non-Employee Chair of the BoardDr. Steven M. Paul M.D.
FounderMs. Daphne Zohar
Co-Founder & Chief Scientific OfficerDr. Michael Cunyuan Chen Ph.D.
Chief Medical Officer & President of Clinical DevelopmentDr. Antony Loebel M.D.
Chief Financial OfficerMs. Lauren A. White M.B.A.